Showing results (101-110 of 114) with videos related to
Sort By:
Pageof 12
Journal of Cardiac Failure|October 1, 2024
The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot TrialJan Biegus, Gad Cotter, Beth A Davison, et al.European Journal of Heart Failure|April 1, 2020
Mega-trials in heart failure: effects of dilution in examination of new therapiesBeth A Davison, Koji Takagi, Stefanie Senger, et al.The American Journal of Cardiology|August 6, 2022
Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies)Beth A Davison, Koji Takagi, Christopher Edwards, et al.International Journal of Cardiology|September 24, 2016
Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failureEline L Vegter, Daniela Schmitter, Yanick Hagemeijer, et al.Circulation. Heart Failure|November 1, 2023
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF RegistryMatteo Pagnesi, Daniele Ghiraldin, Enrico Vizzardi, et al.JACC. Heart Failure|November 15, 2020
Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2Rahul S Loungani, John R Teerlink, Marco Metra, et al.Lancet (London, England)|November 13, 2012
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialJohn R Teerlink, Gad Cotter, Beth A Davison, et al.Journal of the American College of Cardiology|January 1, 2013
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomesMarco Metra, Gad Cotter, Beth A Davison, et al.European Journal of Heart Failure|December 19, 2020
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHFBeth A Davison, Stefanie Senger, Iziah E Sama, et al.Drug Safety|February 21, 2012
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECTJohn R Teerlink, Vicente J Iragui, Jay P Mohr, et al.Pageof 12